FDA-cleared profile

AVIEW

Coreline Soft Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: AVIEW provides CT values for pulmonary tissue from thoracic and cardiac CT datasets. The FDA indication describes lung, lobe, airway, fissure, nodule, and cardiac analysis, including nodule measurements, Lung-RADS support, and coronary calcium scoring, for adult patients.

Clinical role
Medical-image processing, segmentation, enhancement, measurement, quantification, visualization, or reporting support under professional review.
Images and patients
CT/CTA · Chest/lung and heart/coronary arteries
Key limitation
Keep in mind: The FDA indication is limited to adult patients. Quantitative values, segmentation, nodule characterization, Lung-RADS support, and calcium-risk information require qualified-physician review and the exact supported CT inputs.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AVIEW provides CT values for pulmonary tissue from thoracic and cardiac CT datasets. The FDA indication describes lung, lobe, airway, fissure, nodule, and cardiac analysis, including nodule measurements, Lung-RADS support, and coronary calcium scoring, for adult patients.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/lung and heart/coronary arteries Input: Adult thoracic and cardiac CT datasets, including supported sharp-to-soft kernel and single or serial lung-nodule studies.
  • Who uses it?Intended users: Qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow.
  • What does the software produce?Output: Lung, lobe, airway, fissure, and cardiac segmentations; density, size, volume, mass, volume-doubling-time, Lung-RADS, and Agatston, volume, or mass scores; reports and displays.
  • What is its most important limitation?Key limitation: The FDA indication is limited to adult patients. Quantitative values, segmentation, nodule characterization, Lung-RADS support, and calcium-risk information require qualified-physician review and the exact supported CT inputs.

Clinical takeaway. Clinical role: AVIEW provides CT values for pulmonary tissue from thoracic and cardiac CT datasets. The FDA indication describes lung, lobe, airway, fissure, nodule, and cardiac analysis, including nodule measurements, Lung-RADS support, and coronary calcium scoring, for adult patients.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports that substantial equivalence is supported by non-clinical testing, citing the results of software validation and verification testing, and states that a clinical study was not considered necessary and no clinical testing was required because the indications for use are equivalent to the predicate device. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AVIEW provides CT values for pulmonary tissue from thoracic and cardiac CT datasets. The FDA indication describes lung, lobe, airway, fissure, nodule, and cardiac analysis, including nodule measurements, Lung-RADS support, and coronary calcium scoring, for adult patients.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Medical-image processing, segmentation, enhancement, measurement, quantification, visualization, or reporting support under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Adult thoracic and cardiac CT datasets, including supported sharp-to-soft kernel and single or serial lung-nodule studies.
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.

Output and clinician action
Lung, lobe, airway, fissure, and cardiac segmentations; density, size, volume, mass, volume-doubling-time, Lung-RADS, and Agatston, volume, or mass scores; reports and displays.
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.

Care setting
Hospital, clinic, imaging-center, procedural, dental, or other labeled clinical environments.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA indication is limited to adult patients. Quantitative values, segmentation, nodule characterization, Lung-RADS support, and calcium-risk information require qualified-physician review and the exact supported CT inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports that substantial equivalence is supported by non-clinical testing, citing the results of software validation and verification testing, and states that a clinical study was not considered necessary and no clinical testing was required because the indications for use are equivalent to the predicate device. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "This Medical device is not new; therefore, a clinical study was not considered necessary prior to release." … "Additionally, there was no clinical testing required to support the medical device as the indications for use is equivalent to the predicate device.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports that substantial equivalence is supported by non-clinical testing, citing the results of software validation and verification testing, and states that a clinical study was not considered necessary and no clinical testing was required because the indications for use are equivalent to the predicate device. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "This Medical device is not new; therefore, a clinical study was not considered necessary prior to release." … "Additionally, there was no clinical testing required to support the medical device as the indications for use is equivalent to the predicate device.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified. Sensitivity is not promoted as a product-wide endpoint.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified. Specificity is not promoted as a product-wide endpoint.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243689 FDA decision evidence for AVIEW

  • DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
  • PopulationChest/lung and heart/coronary arteries
  • Scopeexact submission
  • Tested versionAVIEW
  • IndependenceSponsor or vendor study

K243689

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243689 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals. Prior source-backed dossier value: The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243689 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult thoracic and cardiac CT datasets, including supported sharp-to-soft kernel and single or serial lung-nodule studies.

    Scope: Exact FDA submission. Prior source-backed dossier value: Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K243689: AVIEW

  2. Routing

    Source context, not route validation: The FDA indication describes CT data storage, transfer, inquiry, and display in on-premises or cloud environments; validate the exact DICOM, identity, routing, archive, and deployment contract locally.

    Scope: Exact FDA submission. The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K243689: AVIEW

  3. AI processing

    Source context, not route validation: The FDA indication describes on-premises and cloud environments; hosting region, availability, security, retention, and contract responsibilities are not established by that indication.

    Scope: Exact FDA submission. The exact FDA material describes this release-level deployment boundary; hosting, contracts, security, availability, and site configuration remain separate evidence. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K243689: AVIEW

  4. Returned objects

    Source context, not route validation: Lung, lobe, airway, fissure, and cardiac segmentations; density, size, volume, mass, volume-doubling-time, Lung-RADS, and Agatston, volume, or mass scores; reports and displays.

    Scope: Exact FDA submission. Prior source-backed dossier value: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K243689: AVIEW

  5. Viewer/worklist/report

    Unresolved route: Lung, lobe, airway, fissure, and cardiac segmentations; density, size, volume, mass, volume-doubling-time, Lung-RADS, and Agatston, volume, or mass scores; reports and displays.

    Scope: Exact FDA submission. Prior source-backed dossier value: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K243689: AVIEW

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA indication describes on-premises and cloud environments; hosting region, availability, security, retention, and contract responsibilities are not established by that indication.
  • Exact FDA submission
  • Checked 2026-09-04

The exact FDA material describes this release-level deployment boundary; hosting, contracts, security, availability, and site configuration remain separate evidence. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA indication describes CT data storage, transfer, inquiry, and display in on-premises or cloud environments; validate the exact DICOM, identity, routing, archive, and deployment contract locally.
  • Exact FDA submission
  • Checked 2026-09-04

The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication is limited to adult patients. Quantitative values, segmentation, nodule characterization, Lung-RADS support, and calcium-risk information require qualified-physician review and the exact supported CT inputs.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243689 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA indication describes CT data storage, transfer, inquiry, and display in on-premises or cloud environments; validate the exact DICOM, identity, routing, archive, and deployment contract locally. Test representative identifiers, geometry, measurements, units, routing, failure handling, and round trips locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The FDA indication describes on-premises and cloud environments; hosting region, availability, security, retention, and contract responsibilities are not established by that indication. Security, availability, retention, and service responsibilities remain unverified.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA indication is limited to adult patients. Quantitative values, segmentation, nodule characterization, Lung-RADS support, and calcium-risk information require qualified-physician review and the exact supported CT inputs.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication is limited to adult patients. Quantitative values, segmentation, nodule characterization, Lung-RADS support, and calcium-risk information require qualified-physician review and the exact supported CT inputs.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Deployment boundary

The FDA material describes on-premises, cloud, mobile, and Chrome access paths; current hosting, service, security, retention, and enabled-module configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243689
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Chest/lung and heart/coronary arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-19
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
35Fields reviewed
11Source classes checked
20Screened PubMed leads
4Screened trial leads
0Unreviewed FDA recall leads

Screened 20 PubMed and four ClinicalTrials.gov records. AVIEW publications use different or unstated AVIEW versions and functions, and all four trials concern the unrelated Ambu aView display; no record links the tested release to K243689. All 24 were quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 4 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs. No public list price for the exact cleared configuration was found.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K243689: AVIEW

    U.S. Food and Drug Administration - Published 2025-03-19 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AVIEW model card (K243689)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, deployment, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K243689 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history